Market Overview

UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution

Related EXEL
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Exelixis' Cometriq Approved in the EU - Analyst Blog

Piper Jaffray reiterated its Neutral rating on Exelixis (NASDAQ: EXEL) and reduced its price target from $5.50 to $4.50.

Piper Jaffray said, "Exelixis raised net proceeds of $120 million by issuing 30 million shares at $4.25 and $250 million from a 4.25% convertible note bringing proforma cash to $665 million. Cabozantinib has a November 29th PDUFA date in medullary thyroid cancer (MTC). Both the COMET-1 and COMET-2 pivotal studies are underway in castrate resistant prostate cancer (CRPC) plus 11 investigator sponsored trials (ISTs) under a CRADA funded by the NCI. … We are trimming our price target to $4.50 from $5.50 to account for dilution from the deals."

Exelixis closed at $4.38 on Friday.

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Most Popular

Related Articles (EXEL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free